Blueprint Medicines Corporation is a global precision therapy company that is inventing life-changing medicines in two areas of allergy/inflammation and oncology/hematology. The Company delivers its approved medicines, including AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib), to patients in the United States and Europe, and it is globally advancing multiple programs for systemic mastocytosis (SM), lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. Its pipelines also include Elenestinib (BLU-263) (KIT), AYVAKIT (avapritinib) (KIT), Wild-type KIT research program, GAVRETO (pralsetinib) (RET), BLU-945 (EGFR), BLU-525 (EGFR), BLU-451 (EGFR exon 20 insertions), BLU-222 (CDK2), AYVAKIT (PDGFRA), GAVRETO (RET), BLU-222 (CDK2) and BLU-852 (MAP4K1). It is developing elenestinib (BLU-263), an investigational, orally available, potent and highly selective KIT inhibitor, for the treatment of indolent SM and other mast cell disorders.

Employees

685

Sector

Biotechnology & Medical Research

Calendar

Jul. 29 - Q2 2025 Earnings Release (Projected)

More about the company

Quotes

Date	Price	Change	Volume
25-07-11	129.30 $	-0.02%	3,480,521
25-07-10	129.33 $	+0.61%	5,983,948
25-07-09	128.55 $	+0.12%	2,996,550
25-07-08	128.40 $	0.00%	2,959,243
25-07-07	128.40 $	+0.04%	1,937,572

Delayed Quote Nasdaq, July 11, 2025 at 04:00 pm EDT

More quotes

Income Statement and Estimates

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

129.30USD

Average target price

130.60USD

Spread / Average Target

+1.01%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Nasdaq Other stock markets 04:00:00 2025-07-11 pm EDT			5-day change	1st Jan Change
129.30 ^USD	-0.02%		+0.74%	+48.25%

Jun. 17	Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129	MT
Jun. 12	Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses	CI

Capitalization	8.37B 7.16B 6.66B 6.21B 11.45B 718B 12.72B 79.91B 30.48B 336B 31.39B 30.74B 1,234B	P/E ratio 2025 *	-177x	P/E ratio 2026 *	154x
Enterprise value	8.3B 7.1B 6.61B 6.15B 11.36B 712B 12.62B 79.25B 30.23B 333B 31.13B 30.49B 1,223B	EV / Sales 2025 *	11.5x	EV / Sales 2026 *	8.36x
Free-Float	98.51%	Yield 2025 *	0.26%	Yield 2026 *	0.26%

Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129	Jun. 17	MT
Blueprint Medicines Corporation Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses	Jun. 12	CI
Blueprint Medicines Announces Data Reinforcing Safety Profile Of Long-Term Ayvakit	Jun. 12	RE
The Week’s Biggest Mergers Unpacked	Jun. 06
Blueprint Medicines Insider Sold Shares Worth $340,033, According to a Recent SEC Filing	Jun. 05	MT
UBS Adjusts Price Target on Blueprint Medicines to $129 From $88, Maintains Neutral Rating	Jun. 05	MT
Citigroup Upgrades Blueprint Medicines to Neutral From Sell, $129 Price Target	Jun. 04	MT
North American Morning Briefing : Futures Rise on -2-	Jun. 04	DJ
Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132	Jun. 03	MT
Wolfe Downgrades Blueprint Medicines to Peer Perform From Outperform	Jun. 03	MT
Stephens Downgrades Blueprint Medicines to Equalweight From Overweight, Adjusts PT to $135 From $150	Jun. 03	MT
TD Cowen Downgrades Blueprint Medicines to Hold From Buy, Price Target is $130	Jun. 03	MT
JPMorgan Downgrades Blueprint Medicines to Neutral From Overweight, Adjusts PT to $129 From $130	Jun. 03	MT

Wells Fargo Downgrades Blueprint Medicines to Equalweight From Overweight, Price Target is $129	Jun. 17	MT
UBS Adjusts Price Target on Blueprint Medicines to $129 From $88, Maintains Neutral Rating	Jun. 05	MT
Citigroup Upgrades Blueprint Medicines to Neutral From Sell, $129 Price Target	Jun. 04	MT
Guggenheim Downgrades Blueprint Medicines to Neutral From Buy, Price Target is $132	Jun. 03	MT
Wolfe Downgrades Blueprint Medicines to Peer Perform From Outperform	Jun. 03	MT

Blueprint Medicines Corporation Stock

Equities

BPMC

US09627Y1091

Biotechnology & Medical Research

Valuation: Blueprint Medicines Corporation

Chart: Blueprint Medicines Corporation

Latest news: Blueprint Medicines Corporation

Last Transcript: Blueprint Medicines Corporation

Analysts' recommendations: Blueprint Medicines Corporation

Press Releases: Blueprint Medicines Corporation

News in other languages: Blueprint Medicines Corporation

Quotes and Performance

Course Extremes

Managers and Directors: Blueprint Medicines Corporation

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysts' Consensus

Quarterly revenue - Rate of surprise

BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC	Jun. 20	BU
BLUEPRINT MEDICINES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Blueprint Medicines Corporation - BPMC	Jun. 03	BU
Sanofi acquires Blueprint Medicines for $9.1 billion	Jun. 02	AQ
Shareholder Alert: The Ademi Firm Investigates Whether Blueprint Medicines Corporation Is Obtaining a Fair Price for Its Public Shareholders	Jun. 02	BU
BPMC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Blueprint Medicines Corporation Is Fair to Shareholders	Jun. 02	BU

Borsa: le principali fusioni della settimana	Jun. 07
Fusiones y adquisiciones: Las operaciones más importantes de la semana	Jun. 07
De grootste fusies van de week ontleed	Jun. 06
Wochen-Überblick: Fusionen und Übernahmen	Jun. 06
Aktien New York: Anleger nehmen weitere Handelsspannungen gelassen auf	Jun. 02

1 day	-0.02%
1 week	+0.74%
Current month	+0.87%
1 month	+1.04%
3 months	+61.08%
6 months	+47.89%
Current year	+48.25%

1 week	128.21	129.49
1 month	127.86	129.49
Current year	73.04	129.49
1 year	73.04	129.49
3 years	37.82	129.49
5 years	37.82	129.49
10 years	13.04	129.49

Manager	Title	Age	Since
Kathryn Haviland CEO	Chief Executive Officer	49	2022-04-03
Michael Landsittel DFI	Director of Finance/CFO	53	2014-08-31
Percy Carter CTO	Chief Tech/Sci/R&D Officer	54	2021-05-18

Director	Title	Age	Since
Alexis Borisy BRD	Director/Board Member	53	2011-04-11
Nicholas Lydon BRD	Director/Board Member	68	2011-04-11
Jeffrey Albers CHM	Chairman	53	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
BLUEPRINT MEDICINES CORPORATION	-0.02%	+0.74%	+11.51%	+128.53%	8.37B
LONZA GROUP AG	-0.95%	+1.29%	+10.59%	-0.35%	50.45B
BEONE MEDICINES LTD.	-1.22%	+1.96%	+71.39%	+32.62%	30.01B
CELLTRION, INC.	0.00%	+3.66%	+5.59%	+11.14%	28.73B
IQVIA HOLDINGS INC.	-1.65%	-0.88%	-23.20%	-25.78%	28.64B
EUROFINS SCIENTIFIC SE	-0.03%	-0.69%	+26.91%	-21.99%	12.7B
ICON PUBLIC LIMITED COMPANY	-1.02%	+0.28%	-54.20%	-30.94%	12.08B
ASCENDIS PHARMA A/S	-0.87%	+0.45%	+27.39%	+86.90%	10.69B
QIAGEN N.V.	-0.87%	-0.43%	+14.05%	-6.03%	10.51B
TEMPUS AI, INC.	-4.56%	-6.71%	+62.51%	-	10.32B
Average	-0.63%	-0.67%	+15.25%	+19.34%	20.25B
Weighted average by Cap.	-0.79%	-0.62%	+15.02%	+9.53%

	2025 *	2026 *
Net sales	721M 617M 574M 534M 986M 61.81B 1.1B 6.88B 2.62B 28.94B 2.7B 2.65B 106B	956M 818M 761M 709M 1.31B 82B 1.45B 9.13B 3.48B 38.39B 3.59B 3.51B 141B
Net income	-43.67M -37.36M -34.77M -32.38M -59.75M -3.75B -66.39M -417M -159M -1.75B -164M -160M -6.44B	72.1M 61.69M 57.4M 53.47M 98.65M 6.18B 110M 688M 263M 2.9B 270M 265M 10.63B
Net Debt	-69.88M -59.79M -55.64M -51.82M -95.61M -5.99B -106M -667M -254M -2.81B -262M -257M -10.3B	-378M -324M -301M -280M -517M -32.43B -575M -3.61B -1.38B -15.18B -1.42B -1.39B -55.73B